BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
  • Interviews
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence
Back to Companies Directory

XtalPi

XtalPi logo

Website
http://www.xtalpi.com/
Founded
2014

Technologies

AI Companies (Drug Discovery) Pharmaceutical and Drug Discovery Quantum Theory in Drug Discovery

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform. Through its tightly interwoven quantum mechanics, artificial intelligence, and high-performance cloud computing algorithms, the ID4 platform enables pharmaceutical companies to increase their efficiency, accuracy, and success rate at critical stages of drug R&D. By accelerating the pace of drug discovery and development, XtalPi aims to contribute to a healthier society worldwide.

Founded in 2014 by a group of quantum physicists at MIT, XtalPi has since grown into an elite team of researchers with multi-disciplinary expertise in physics, chemistry, pharmaceutical R&D, and algorithm design. XtalPi has received much recognition for its cutting-edge technologies, its innovative solutions, and the breadth of potential applications of its offerings across the pharmaceutical value chain, which has allowed it to gain industry approval and establish strategic partnerships with several top international pharmaceutical companies. Its recently completed Series B funding round through Sequoia China, Tencent, and Google makes XtalPi one of the best-funded AI companies in biotechnology.


Articles Mentioning This Company

The Quantum Drug Discovery Tracker

The Quantum Drug Discovery Tracker

Nov. 17, 2026     Articles
Latest changes · November 16, 2026 First edition as a living tracker, replacing our February 2024 article. 10 companies added. Roivant Discovery is now PsiThera, an independent company with a $47.5M Series A. Zapata shut down in October 2024 and is back as Zapata Quantum after a $15M round. Algorithmiq …
13 AI Drug Discovery Companies to Watch in 2026

13 AI Drug Discovery Companies to Watch in 2026

Oct. 15, 2026     Articles
AI drug discovery has moved from platform pitches to clinical tests. One recent sign: in October 2026, Iambic Therapeutics raised $150 million in a Nasdaq IPO, saying in its filing that its AI approach can "disrupt legacy drug discovery paradigms." Investors and pharma partners increasingly judge companies like Iambic on …
How Big Pharma Adopts AI To Boost Drug Discovery

How Big Pharma Adopts AI To Boost Drug Discovery

Oct. 9, 2025     Articles
(Last updated: October 2025) Since 1950, when Alan Turing introduced the concept of 'thinking machines', artificial intelligence has steadily advanced—from the rise of neural networks in the 1980s to the release of OpenAI’s GPT-3 in 2020, which paved the way for ChatGPT in 2022. Today, AI has become an integral …
2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

March 15, 2018     Articles
(Last updated: 15.03.2018) The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a notable amount of activity over the last several years with a considerable number of initiated research collaborations between AI-driven R&D vendors and top …

R&D Platform

With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi’s ID4 platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development.

News

  • 2024-10-11
    XtalPi’s Ailux Biologics Enters License Agreement with Janssen Biotech to Advance AI-Powered Biologics Discovery
  • 2024-04-03
    New Landmark Report Unveils a Decade of AI Transformation in Drug Discovery

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Outsourced R&D
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar
  • Sponsored Content

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.

Sign in or create an account